Optimized High-Titer Lentivirus Production and Efficient CAR-T Cell Generation

Area of Science:

• Biotechnology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR)-T cell therapy shows high efficacy in B-cell malignancies and emerging potential in autoimmune diseases.
• Current CAR-T cell manufacturing is hindered by challenges in producing critical components like high-titer lentiviral vectors (LVs).
• Lack of optimized protocols complicates CAR-T cell production, limiting accessibility.

Purpose of the Study:

• To optimize lentiviral vector (LV) production for enhanced viral titers.
• To develop a scalable, reproducible, and economical framework for CAR-T cell manufacturing.
• To facilitate preclinical and translational research by streamlining CAR-T cell generation.

Main Methods:

• Optimized LV production by screening plasmid ratios and enhancing transfection efficiency in HEK293T cells.
• Fine-tuned peripheral blood mononuclear cell (PBMC) activation and transduction conditions.
• Developed protocols for scalable production of third-generation LVs and CAR-T cell generation.

Main Results:

• Achieved enhanced viral titers through optimized LV production methods.
• Established a reproducible and economical process for generating CAR-T cells.
• Provided a framework for efficient CAR-T cell manufacturing.

Conclusions:

• Optimized LV production protocols significantly improve CAR-T cell manufacturing.
• The developed methods facilitate scalable, reproducible, and cost-effective CAR-T cell generation.
• This work supports broader accessibility and application of CAR-T cell therapies.